SCHEMBL5865578

SCHEMBL5865578

FC(F)(F)c1cc(C(=C(Cl)Cl)c2ccc(Br)cc2)ccc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
XBP1 P17861 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 2/20 0.42
NOTUM Q6P988 2/20 0.40
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EPHX1 P07099 2/20 0.38
TMPRSS4 Q9NRS4 1/20 0.37
DDR1 Q08345 1/20 0.37
TAS2R14 Q9NYV8 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865631 0.89 NOTUM (0.53) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL5865199 0.89 CYP3A4 (0.55) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL5865640 0.87 NPFFR2 (0.44) MAPTMEN1KMT2ALMNANOTUM
SCHEMBL5865501 0.84 CYP3A4 (0.40) MAPTMEN1KMT2ARAB9ALMNA
SCHEMBL12097542 0.79 MAPT (0.54) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL27130155 0.79 MAPT (0.41) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL27007676 0.79 MAPT (0.41) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL9494805 0.78 TSHR (0.59) MAPTMEN1KMT2ALMNACYP3A4
SCHEMBL5865588 0.78 CYP3A4 (0.53) MAPTNPSR1XBP1MEN1KMT2A
SCHEMBL27007990 0.75 MAPT (0.58) MAPTNPSR1XBP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP disclosed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 MAPT 4158/4885NPSR1 99/4885XBP1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.